Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
10.27
+0.29 (2.91%)
Jun 29, 2026, 3:17 PM EDT - Market open
Immix Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Immix Biopharma stock have an average target of 19.4, with a low estimate of 15 and a high estimate of 23. The average target predicts an increase of 88.90% from the current stock price of 10.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immix Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Initiates $19 | Buy | Initiates | $19 | +85.00% | Jun 17, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Maintains $15 | Buy | Maintains | $15 | +46.06% | May 26, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $15 → $20 | Buy | Reiterates | $15 → $20 | +94.74% | May 22, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $20 | Buy | Reiterates | $20 | +94.74% | Mar 25, 2026 |
| Citizens JMP | Citizens JMP | Buy Initiates $23 | Buy | Initiates | $23 | +123.95% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.13M
EPS This Year
-0.69
from -0.89
EPS Next Year
-0.74
from -0.69
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 93.9M | |
| Avg | n/a | 45.1M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 782.3% |
| Avg | - | 295.8% |
| Low | - | 105.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.57 | -0.08 | |
| Avg | -0.69 | -0.74 | |
| Low | -0.87 | -1.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.